지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2016.1
- 수록면
- 391 - 398 (8page)
이용수
초록· 키워드
오류제보하기
Background/Aims: Two comparable anti-tumor necrosis factor (TNF) agents with different routes of administration (intravenous [iv] infliximab [IFX] vs subcutaneous [sc] adalimumab [ADA]) are available for patients with Crohn’s disease (CD) in Korea. This study aimed to identify the preferences of Korean CD patients for a specific anti-TNF agent and the factors contributing to the decision. Methods: A prospective survey was performed among anti-TNF-naive CD patients in 10 tertiary referral hospitals. A 16-item questionnaire addressed patient preferences and the factors contributing to the decision in favor of a particular anti-TNF agent. A logistic regression was conducted to assess predictive factors for ADA preference. Results: Overall, 189 patients (139 males; mean age, 32.47±11.71 years) completed the questionnaire.
IFX and ADA were preferred by 63.5% (120/189) and 36.5% (69/189) of patients, respectively. The most influential reason for choosing IFX was ‘doctor’s presence’ (68.3%, 82/120), and ADA was “easy to use” (34.8%, 24/69). Amid various clinicodemographic data, having a >60-minute travel time to the hospital was a significant independent predictive factor for ADA preference. Conclusions: A large number of anti-TNF-naive Korean patients with CD preferred anti-TNFs with an iv route of administration. The reassuring effect of a doctor’s presence might be the main contributing factor for this decision.
목차
등록된 정보가 없습니다.
참고문헌 (32)
참고문헌 신청
Vermeire S / 2007 / Review article: altering the natural history of Crohn’s disease: evidence for and against current therapies / Aliment Pharmacol Ther 25:3~12
Reinecker HC / 1993 / Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease / Clin Exp Immunol 94:174~181
van Assche G / 2010 / Mucosal healing and anti TNFs in IBD / Curr Drug Targets 11:227~233
Chen-Wang Chang / 2014 / Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn’s Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study / Intestinal research 12(4):287~292
김남희 / 2014 / Long-Term Clinical Outcomes of Korean Patient With Crohn’s Disease Following Early Use of Infliximab / Intestinal research 12(4):281~286
Reinecker HC / 1993 / Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease / Clin Exp Immunol 94:174~181
van Assche G / 2010 / Mucosal healing and anti TNFs in IBD / Curr Drug Targets 11:227~233
Chen-Wang Chang / 2014 / Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn’s Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study / Intestinal research 12(4):287~292
김남희 / 2014 / Long-Term Clinical Outcomes of Korean Patient With Crohn’s Disease Following Early Use of Infliximab / Intestinal research 12(4):281~286
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients
Journal of Korean Medical Science
2017 .01
-
Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn’s Disease: A Systematic Review of Real-World Evidence Studies
Pediatric Gastroenterology, Hepatology & Nutrition
2020 .01
-
Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
Gut and Liver
2021 .01
-
Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease
Gut and Liver
2021 .01
-
Efficacy of restarting anti-tumor necrosis factor α agents after surgery in patients with Crohn’s disease
Intestinal research
2018 .01
-
Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study
Gut and Liver
2021 .09
-
Patients’ Preference for a Specific Anti-Tumor Necrosis Factor Agent: Korea versus Western
Gut and Liver
2016 .01
-
Short-Term Outcome of Infliximab Therapy in Pediatric Crohn’s Disease: A Single-Center Experience
Pediatric Gastroenterology, Hepatology & Nutrition
2017 .01
-
Impact of anti-tumor necrosis factor treatment on lipid profiles in Korean patients with ankylosing spondylitis
대한류마티스학회지
2024 .01
-
Comparison of time until elective intestinal resection regarding previous anti-tumor necrosis factor exposure: a Brazilian study on patients with Crohn’s disease
Intestinal research
2018 .01
-
Outcomes of limited period of adalimumab treatment in moderate to severe Crohn’s disease patients: Taiwan Society of Inflammatory Bowel Disease Study
Intestinal research
2017 .01
-
Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn’s disease
Intestinal research
2022 .07
-
Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy
Intestinal research
2017 .01
-
Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
Gut and Liver
2017 .01
-
Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management
Intestinal research
2018 .01
-
Correlation of serum levels of anti-tumor necrosis factor agents with perianal fistula healing in Crohn’s disease: a narrative review
Intestinal research
2021 .01
-
The Long-Term Effect of Early Anti-Tumor Necrosis Factor on Restoration of Growth in Pediatric Crohn’s Disease
Gut and Liver
2018 .01
-
Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study
Yonsei Medical Journal
2020 .01
-
Long-Term Durability of Infliximab for Pediatric Ulcerative Colitis: A Retrospective Data Review in a Tertiary Children's Hospital in Japan
Pediatric Gastroenterology, Hepatology & Nutrition
2021 .01
-
Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment
Intestinal research
2018 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0